| Code | CSB-RA021334MB8HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to the reference antibody JY47, targeting signal regulatory protein alpha (SIRPA, also known as CD172a). SIRPA is an inhibitory receptor expressed primarily on myeloid cells, including macrophages, dendritic cells, and neutrophils, where it plays a critical role in regulating innate immune responses. Upon binding to its ligand CD47, SIRPA transmits "don't eat me" signals that inhibit phagocytosis, allowing cells to evade immune surveillance. This checkpoint mechanism is frequently exploited by cancer cells to escape macrophage-mediated destruction, making SIRPA a significant target in immuno-oncology research. Dysregulation of the SIRPA-CD47 axis has been implicated in various malignancies, autoimmune disorders, and inflammatory conditions.
The reference antibody JY47 is a well-characterized research tool used extensively to study SIRPA function and the CD47-SIRPA signaling pathway. This biosimilar provides researchers with a reliable reagent for investigating macrophage biology, tumor immune evasion mechanisms, and potential therapeutic interventions targeting the innate immune checkpoint. It is suitable for exploring SIRPA-mediated cellular interactions and evaluating novel immunotherapeutic strategies.
There are currently no reviews for this product.